RU94037557A - Способ лечения патологических отклонений при диабете типа ii - Google Patents
Способ лечения патологических отклонений при диабете типа iiInfo
- Publication number
- RU94037557A RU94037557A RU94037557/14A RU94037557A RU94037557A RU 94037557 A RU94037557 A RU 94037557A RU 94037557/14 A RU94037557/14 A RU 94037557/14A RU 94037557 A RU94037557 A RU 94037557A RU 94037557 A RU94037557 A RU 94037557A
- Authority
- RU
- Russia
- Prior art keywords
- insulin
- term
- long
- diabetes
- bromocriptine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Способ долгосрочной модификации и регуляции липидного и углеводного метаболизма, для уменьшения ожирения, резистентности к инсулину и гиперинсулинемии и гипергликемии или и того и другого (отличительных признаков инсулиннезависимого, или диабета типа II), посредством введения (орально, сублингвально или парентерально) позвоночным, человеку или животным агониста допамина, например бромкриптина. Введение бромкриптина производится в определенное, ограниченное время дня, в зависимости от нормального циркадного ритма инсулинрезистентных и инсулинчувствительных представителей сходных видов. Устойчивость к инсулину, гиперинсулинемии и гипергликемии или и то и другое можно контролировать у человека на долгосрочной основе с помощью этого лечения ввиду того, что краткосрочное дневное введение препарата исправляет гормональное "расписание" в нервных центрах головного мозга, что производит долгосрочный эффект.
Claims (1)
- Способ долгосрочной модификации и регуляции липидного и углеводного метаболизма, для уменьшения ожирения, резистентности к инсулину и гиперинсулинемии и гипергликемии или и того и другого (отличительных признаков инсулиннезависимого, или диабета типа II), посредством введения (орально, сублингвально или парентерально) позвоночным, человеку или животным агониста допамина, например бромкриптина. Введение бромкриптина производится в определенное, ограниченное время дня, в зависимости от нормального циркадного ритма инсулинрезистентных и инсулинчувствительных представителей сходных видов. Устойчивость к инсулину, гиперинсулинемии и гипергликемии или и то и другое можно контролировать у человека на долгосрочной основе с помощью этого лечения ввиду того, что краткосрочное дневное введение препарата исправляет гормональное "расписание" в нервных центрах головного мозга, что производит долгосрочный эффект.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US813135 | 1985-12-24 | ||
| US81313591A | 1991-12-23 | 1991-12-23 | |
| US813.135 | 1991-12-23 | ||
| PCT/US1992/011166 WO1993012793A1 (en) | 1991-12-23 | 1992-12-22 | A therapeutic process for the treatment of the pathologies of type ii diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU94037557A true RU94037557A (ru) | 1996-05-20 |
| RU2104698C1 RU2104698C1 (ru) | 1998-02-20 |
Family
ID=25211542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU94037557A RU2104698C1 (ru) | 1991-12-23 | 1992-12-22 | Способ лечения патологических отклонений при диабете типа ii |
Country Status (5)
| Country | Link |
|---|---|
| AU (1) | AU3419293A (ru) |
| CZ (1) | CZ282909B6 (ru) |
| HU (1) | HUT67688A (ru) |
| RU (1) | RU2104698C1 (ru) |
| WO (1) | WO1993012793A1 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585347A (en) * | 1988-05-10 | 1996-12-17 | Ergo Science Incorporated | Methods for the determination and adjustment of prolactin daily rhythms |
| US5744477A (en) * | 1988-05-10 | 1998-04-28 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for treatment of obesity using prolactin modulators and diet |
| US5696128A (en) * | 1994-07-07 | 1997-12-09 | The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College | Method of regulating immune function |
| IL112106A0 (en) * | 1993-12-22 | 1995-03-15 | Ergo Science Inc | Accelerated release composition containing bromocriptine |
| DE69736928T2 (de) * | 1996-05-07 | 2007-06-28 | Pliva Istrazivanje I Razvoj D.O.O. | Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus |
| US9655865B2 (en) * | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| AU2013263800B2 (en) * | 2007-03-30 | 2016-05-05 | Veroscience Llc | Methods of treating metabolic syndrome using dopamine receptor agonists |
| WO2009062113A1 (en) * | 2007-11-07 | 2009-05-14 | Burnham Institute For Medical Research | Method and compounds for modulating insulin production |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| AU2014277952A1 (en) * | 2013-06-13 | 2016-01-28 | Veroscience Llc | Compositions and methods for treating metabolic disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4659715A (en) * | 1986-03-07 | 1987-04-21 | Louisiana State University And Agricultural And Mechanical College | Method of inhibiting body fat stores |
| DE3722383A1 (de) * | 1986-07-14 | 1988-01-28 | Sandoz Ag | Neue verwendung von bromocriptin |
-
1992
- 1992-12-22 AU AU34192/93A patent/AU3419293A/en not_active Abandoned
- 1992-12-22 HU HU9401900A patent/HUT67688A/hu unknown
- 1992-12-22 CZ CZ941554A patent/CZ282909B6/cs unknown
- 1992-12-22 RU RU94037557A patent/RU2104698C1/ru not_active IP Right Cessation
- 1992-12-22 WO PCT/US1992/011166 patent/WO1993012793A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| HU9401900D0 (en) | 1994-09-28 |
| CZ282909B6 (cs) | 1997-11-12 |
| WO1993012793A1 (en) | 1993-07-08 |
| HUT67688A (en) | 1995-04-28 |
| RU2104698C1 (ru) | 1998-02-20 |
| AU3419293A (en) | 1993-07-28 |
| CZ155494A3 (en) | 1995-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cardinali et al. | Basic aspects of melatonin action | |
| RU94037557A (ru) | Способ лечения патологических отклонений при диабете типа ii | |
| Pandi-Perumal et al. | Role of the melatonin system in the control of sleep: therapeutic implications | |
| ES2126563T3 (es) | Uso de compuestos inhibidores de prolactina para reajuste del ritmo circadiano de prolactina. | |
| Wurtman et al. | Control of brain monoamine synthesis by diet and plasma amino acids | |
| Hering et al. | Sodium valproate in the treatment of cluster headache: an open clinical trial | |
| Cahill et al. | Circadian regulation of melatonin in the retina of Xenopus laevis: limitation by serotonin availability | |
| Tobler et al. | Effects of melatonin and the melatonin receptor agonist S‐20098 on the vigilance states, EEG spectra, and cortical temperature in the rat | |
| Viggiano et al. | Anticonvulsant properties of an oral ketone ester in a pentylenetetrazole-model of seizure | |
| CA1267094A (en) | Therapeutic drug for dementia | |
| McCann et al. | Major metabolites of (±) 3, 4-methylenedioxyamphetamine (MDA) do not mediate its toxic effects on brain serotonin neurons | |
| Kumar | Melatonin: a master hormone and a candidate for universal panacea | |
| Masuda et al. | Intrinsic activity rhythms in Macaca mulatta: their entrainment to light and melatonin | |
| Perlow et al. | Daily rhythms in cortisol and melatonin in primate cerebrospinal fluid: effects of constant light and dark | |
| Black et al. | Elevation and depression of hepatic tyrosine transaminase activity by depletion and repletion of norepinephrine. | |
| Hutton et al. | Treatment of chronic Parkinson's disease with controlled-release carbidopa/levodopa | |
| Akanmu et al. | A novel melatonin derivative modulates sleep–wake cycle in rats | |
| Lewy et al. | Pretreatment circadian period in free-running blind people may predict the phase angle of entrainment to melatonin | |
| Bolliet et al. | Regulation of melatonin secretion by light in the isolated pineal organ of the white sucker (Catostomus commersoni) | |
| Reis | Brain Monoamines in Aggression and Sleep: Chapter 23 | |
| Gouveia et al. | Patterns of respiration in Locusta migratoria nymphs when feeding | |
| BR0108261A (pt) | Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono | |
| Boggio et al. | Cerebroventricular administration of interferon-gamma modifies locomotor activity in the golden hamster | |
| Pscheidt et al. | Excretion of catecholamines and exacerbation of symptoms in schizophrenic patients | |
| Mazzucchelli et al. | Ultradian rhythms in the N1-P2 amplitude of the visual evoked potential in two inbred strains of mice: DBA/2J and C57BL/6 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20111223 |